Leukaemia

Leukaemia constitutes a range of cancers, typically originating in the bone marrow, and resulting in overproduction of abnormal blood cells. It is a common condition, with

...


Read more on Leukaemia

 

 

Latest news articles

Added 7 days ago Drug news

NICE recommends use of Vyxeos in acute myeloid leukemia.- Jazz Pharma.

The UK National Institute for Health and Care Excellence (NICE) has recommended Vyxeos (daunorubicin and cytarabine), from Jazz Pharma, for...

Added 13 days ago Drug news

Sandoz will not pursue its submission for biosimilar rituximab in the US.

Sandoz, announced that it will not pursue its submission for biosimilar rituximab in the US at this time. The decision...

Added 14 days ago Drug news

EU approves Venclyxto + MabThera for chronic lymphocytic leukaemia.- Roche.

Roche announced that the European Commission has approved Venclyxto (venetoclax) in combination with MabThera (rituximab) for the treatment of adult...

Search all news articles for Leukaemia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia...

Added 6 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 2 years ago

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.

Added 2 years ago

Search all guidelines for Leukaemia
 

Journal articles

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.

Added 3 months ago

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction...

Added 4 months ago

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Purpose: Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia...

Added 5 months ago

Search all journal articles for Leukaemia
 

Clinical trials

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)

The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine.

Added 1 year ago

A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)

This study consists of two portions: The first portion- Phase 1, or dose-escalation portion, that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDC)...

Added 5 years ago

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with...

Added 4 months ago

Search all clinical trials for Leukaemia
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Personalisation of chronic lymphocytic leukaemia (CLL) care

Personalisation of chronic lymphocytic leukaemia (CLL) care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Leukaemia